Abstract
There is pressing need to better understand pharmacokinetics in critically ill patients. This will aid clinicians in selecting optimal dosing regimens. Pharmacokinetic studies are difficult in this population due to the heterogeneity of the patients and the practical issues of research involving critically ill patients. Therapeutic drug monitoring is routinely performed to guide dosing for aminoglycoside and glycopeptide antibiotics. Expanding its use to other drug classes could provide new therapeutic advantages. Plasma concentration may not always reflect tissue distribution in critically ill patients. Microdialysis is a technique that can be applied in the Intensive Care Unit to measure tissue concentrations and provide further insights to antimicrobial therapy for critically ill patients. Finally, the application of population pharmacokinetic analysis in studies in critically ill patients may identify factors affecting pharmacokinetics and enhance drug dosing regimens for varied patient groups.
Keywords: Critically ill patient, microdialysis, pharmacodynamics, physiology, population pharmacokinetics, therapeutic drug monitoring., Intensive Care Unit, glycopeptide antibiotics, enhance drug dosing regimens, pharmacodynamic properties, optimal drug dosage, large variability exists, patient's clinical management, bioanalytical method
Current Pharmaceutical Biotechnology
Title: How to Measure Pharmacokinetics in Critically Ill Patients?
Volume: 12 Issue: 12
Author(s): Xin Liu, Peter S. Kruger and Michael S. Roberts
Affiliation:
Keywords: Critically ill patient, microdialysis, pharmacodynamics, physiology, population pharmacokinetics, therapeutic drug monitoring., Intensive Care Unit, glycopeptide antibiotics, enhance drug dosing regimens, pharmacodynamic properties, optimal drug dosage, large variability exists, patient's clinical management, bioanalytical method
Abstract: There is pressing need to better understand pharmacokinetics in critically ill patients. This will aid clinicians in selecting optimal dosing regimens. Pharmacokinetic studies are difficult in this population due to the heterogeneity of the patients and the practical issues of research involving critically ill patients. Therapeutic drug monitoring is routinely performed to guide dosing for aminoglycoside and glycopeptide antibiotics. Expanding its use to other drug classes could provide new therapeutic advantages. Plasma concentration may not always reflect tissue distribution in critically ill patients. Microdialysis is a technique that can be applied in the Intensive Care Unit to measure tissue concentrations and provide further insights to antimicrobial therapy for critically ill patients. Finally, the application of population pharmacokinetic analysis in studies in critically ill patients may identify factors affecting pharmacokinetics and enhance drug dosing regimens for varied patient groups.
Export Options
About this article
Cite this article as:
Liu Xin, S. Kruger Peter and S. Roberts Michael, How to Measure Pharmacokinetics in Critically Ill Patients?, Current Pharmaceutical Biotechnology 2011; 12 (12) . https://dx.doi.org/10.2174/138920111798808239
DOI https://dx.doi.org/10.2174/138920111798808239 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Pulmonary Circulation and Pulmonary Function in Neonatal Lung Hypoplasia:Treatment with Corticosteroids
Current Pediatric Reviews Diabetic Retinopathy, Superoxide Damage and Antioxidants
Current Pharmaceutical Biotechnology Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Appraisal of AβPP Transgenic Mice as Models for Alzheimers Disease Amyloid Cascade
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science Respiratory Hypoxia and Oxidative Stress in the Brain. Is the Endogenous Erythropoietin an Antioxidant?
Current Chemical Biology Diagnosis and Management of Hypertensive Emergencies Complicating Pregnancy
Current Women`s Health Reviews Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Nitric Oxide and Disorders of the Erythrocyte: Emerging Roles and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Current Concepts and Controversies in the Use of Antenatal Corticosteroid Therapy for Prevention of Neonatal Morbidities
Current Women`s Health Reviews Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Trojan Microparticles Potential for Ophthalmic Drug Delivery
Current Medicinal Chemistry Incorporation of Anti-angiogenic Therapies in the Treatment of Epithelial Ovarian Cancer: Current Perspectives and Future Directions
Current Angiogenesis (Discontinued) Carbon Monoxide in Acute Lung Injury
Current Pharmaceutical Biotechnology Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)